1. Search Result
Search Result
Results for "

ErbB

" in MedChemExpress (MCE) Product Catalog:

119

Inhibitors & Agonists

1

Screening Libraries

5

Peptides

23

Inhibitory Antibodies

2

Natural
Products

100

Recombinant Proteins

11

Isotope-Labeled Compounds

19

Antibodies

12

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-168438

    EGFR Akt ERK Cardiovascular Disease
    ERBB agonist-1 (Compound EF-1) is an agonist for ERBB4, that activates the ERBB4 signaling pathway by inducing dimerization of the ERBB4 receptor with an EC50 of 10.5 μM. ERBB agonist-1 induces phosphorylation of Akt and ERK1/2, reduces the collagen expression in cardiac fibroblasts, inhibits H2O2-induced cardiomyocyte death and Ang II (HY-13948)-induced cardiomyocyte hypertrophy. ERBB agonist-1 prevents fibrosis and exhibits cardioprotective efficacy in mouse models .
    ERBB agonist-1
  • HY-P4082

    HER2-binding peptide

    EGFR Cancer
    ErbB-2-binding peptide (HER2-binding peptide) is a tumor-binding peptide. ErbB-2-binding peptide has the potential for cancer research .
    ErbB-2-binding peptide
  • HY-P10981

    PI3K Ligands for E3 Ligase Cancer
    ErbB2 peptide is a peptide ligand of E3 ubiquitin ligase targeting PI3K for peptide PROTACs .
    ErbB2 peptide
  • HY-RS04469

    Small Interfering RNA (siRNA) EGFR Others

    ERBB3 Human Pre-designed siRNA Set A contains three designed siRNAs for ERBB3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ERBB3 Human Pre-designed siRNA Set A
    ERBB3 Human Pre-designed siRNA Set A
  • HY-RS04466

    Small Interfering RNA (siRNA) EGFR Others

    ERBB2 Human Pre-designed siRNA Set A contains three designed siRNAs for ERBB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ERBB2 Human Pre-designed siRNA Set A
    ERBB2 Human Pre-designed siRNA Set A
  • HY-RS04474

    Small Interfering RNA (siRNA) EGFR Others

    Erbb4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Erbb4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Erbb4 Rat Pre-designed siRNA Set A
    Erbb4 Rat Pre-designed siRNA Set A
  • HY-RS04468

    Small Interfering RNA (siRNA) Others

    ERBB2 Rat Pre-designed siRNA Set A contains three designed siRNAs for ERBB2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ERBB2 Rat Pre-designed siRNA Set A
    ERBB2 Rat Pre-designed siRNA Set A
  • HY-RS04473

    Small Interfering RNA (siRNA) EGFR Others

    Erbb4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Erbb4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Erbb4 Mouse Pre-designed siRNA Set A
    Erbb4 Mouse Pre-designed siRNA Set A
  • HY-RS04471

    Small Interfering RNA (siRNA) EGFR Others

    Erbb3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Erbb3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Erbb3 Rat Pre-designed siRNA Set A
    Erbb3 Rat Pre-designed siRNA Set A
  • HY-RS04472

    Small Interfering RNA (siRNA) EGFR Others

    ERBB4 Human Pre-designed siRNA Set A contains three designed siRNAs for ERBB4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ERBB4 Human Pre-designed siRNA Set A
    ERBB4 Human Pre-designed siRNA Set A
  • HY-RS04467

    Small Interfering RNA (siRNA) EGFR Others

    Erbb2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Erbb2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Erbb2 Mouse Pre-designed siRNA Set A
    Erbb2 Mouse Pre-designed siRNA Set A
  • HY-RS04470

    Small Interfering RNA (siRNA) EGFR Others

    Erbb3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Erbb3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Erbb3 Mouse Pre-designed siRNA Set A
    Erbb3 Mouse Pre-designed siRNA Set A
  • HY-P99268

    SAR 256212; MM 121; Anti-Human ErbB3/ErbB 3 Recombinant Antibody

    EGFR Apoptosis Cancer
    Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .
    Seribantumab
  • HY-103440

    EGFR Cancer
    EGFR/ErbB-2/ErbB-4 inhibitor-3 (compound 29) is a potent tyrosine kinase inhibitor with IC50s of 0.3, 1.1, 0.5, 2.5, 24 nM for erbB1, erbB2, erbB4, EGF, HER, respectively . EGFR/ErbB-2/ErbB-4 inhibitor-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    EGFR/ErbB-2/ErbB-4 inhibitor-3
  • HY-112420

    EGFR Cancer
    EGFR/ErbB-2/ErbB-4 inhibitor-2 (Compound 5) is a EGFR and ErbB inhibitor with IC50s of 0.017 μM, 0.08 μM, 1.91 μM .
    EGFR/ErbB-2/ErbB-4 inhibitor-2
  • HY-156639

    EGFR Cancer
    EGFR/ErbB-2 inhibitor-1 is a ErbB2/HER2 inhibitor .
    EGFR/ErbB-2 inhibitor-1
  • HY-43533
    Tarlox-TKI
    1 Publications Verification

    EGFR Cancer
    Tarlox-TKI, the active metabolite of Tarloxotinib, is an irreversible pan-ErbB TKI (Tarlox-TKI) .
    Tarlox-TKI
  • HY-P991241

    EGFR Cancer
    Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor, targeting to human ERBB3/HER3.
    Anti-ERBB3/HER3 (29Z6)
  • HY-P991245

    EGFR Cancer
    Anti-ERBB3/HER3 (SGP1) is a human monoclonal antibody (mAb) targeting ERBB3/HER3. Anti-ERBB3/HER3 (SGP1) inhibits Neuregulin stimulated growth of cultured breast cancer cells. Anti-ERBB3/HER3 (SGP1) can be used in breast cancer research .
    Anti-ERBB3/HER3 (SGP1)
  • HY-P990408

    EGFR Inflammation/Immunology
    The Anti-ERBB1/EGFR/HER1 Antibody is a CHO-expressed human antibody that targets ERBB1/EGFR/HER1. The Anti-ERBB1/EGFR/HER1 Antibody consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-ERBB1/EGFR/HER1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-ERBB1/EGFR/HER1 Antibody
  • HY-P99304

    Anti-Human ErbB3 Recombinant Antibody

    EGFR Cancer
    Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody that can be used for the research of cancer .
    Lumretuzumab
  • HY-110039

    EGFR Infection
    BIBX 1382 dihydrochloride is an ErbB kinase inhibitor with significant antiviral activity. BIBX 1382 affects the ability of viruses to enter host cells by inhibiting members of the ErbB kinase family. It can be used to study the interaction mechanism between virus and host and the broad spectrum intervention of highly pathogenic viruses .
    BIBX 1382 dihydrochloride
  • HY-103441

    EGFR Cancer
    JNJ28871063 hydrochloride is an orally active, highly selective and ATP competitive pan-ErbB kinase inhibitor with IC50 values of 22 nM, 38 nM, and 21 nM for ErbB1, ErbB2, and ErbB4, respectively. JNJ28871063 hydrochloride inhibits phosphorylation of functionally important tyrosine residues in both EGFR and ErbB2. JNJ28871063 hydrochloride crosses the blood-brain barrier and has antitumor activity in human tumor xenograft models that overexpress EGFR and ErbB2 .
    JNJ28871063 hydrochloride
  • HY-P99275
    Patritumab
    1 Publications Verification

    Human Anti-ErbB3 Recombinant Antibody

    EGFR Akt ERK PARP Survivin Cancer
    Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
    Patritumab
  • HY-143874

    EGFR Cancer
    HER2-IN-7 is a potent inhibitor of HER2. Deregulation of ErbB family signalling modulates proliferation, invasion, metastasis, angiogenesis, and tumour cell survival. HER2-IN-7 has the potential for the research of diseases associated ErbBs (especially HER2), including cancer (extracted from patent WO2019214634A1, compound 23) .
    HER2-IN-7
  • HY-137028

    PD157432

    EGFR Cancer
    2'-Thioadenosine (PD157432) is a selective and irreversible inhibitor of ErbB-1 and ErbB-2, with an IC50 of 45 µM for ErbB-2. 2'-Thioadenosine covalently inactivates ErbB-1 via modification of a cysteine residue at the active site .
    2′-Thioadenosine
  • HY-153856

    EGFR Cancer
    TAS2940 is a brain-penetrable, orally active, irreversible and selective pan-ERBB inhibitor. TAS2940 against wild-type HER2, HER2 V777L, and A775_G776insYVMA with IC50 values of 5.6 nM, 2.1 nM, and 1.0 nM, respectively. TAS2940 can be used for the study of tumors with HER2 and EGFR aberrations .
    TAS2940
  • HY-153856A

    EGFR Cancer
    TAS2940 fumarate is a brain-penetrable, orally active, irreversible and selective pan-ERBB inhibitor. TAS2940 fumarate against wild-type HER2, HER2 V777L, and A775_G776insYVMA with IC50 values of 5.6 nM, 2.1 nM, and 1.0 nM, respectively. TAS2940 fumarate can be used for the study of tumors with HER2 and EGFR aberrations .
    TAS2940 fumarate
  • HY-P991524

    EGFR Cancer
    MM-111 is a bispecific antibody fusion protein targeting the ErbB2/ErbB3 oncogenic unit. MM-111 blocks activation of the PI3K pro-survival pathway. MM-111 binds to the ErbB2 receptor, which localizes the bispecific molecule to ErbB2 over-expressing tumor cells and promotes binding of the anti-ErbB3 arm to the ErbB3 receptor. MM-111 binding to ErbB3 results in inhibition of ErbB3 signaling by blocking the binding of the ErbB3 physiological ligand heregulin. MM-111 can be used for the study of ErbB2 over-expressing breast tumors .
    MM-111
  • HY-50898
    Lapatinib
    Maximum Cited Publications
    81 Publications Verification

    GW572016; GW2016

    EGFR Autophagy Ferroptosis Cancer
    Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib
  • HY-50898B
    Lapatinib ditosylate monohydrate
    Maximum Cited Publications
    81 Publications Verification

    GW572016 ditosylate monohydrate; GW2016 ditosylate monohydrate

    EGFR Autophagy Ferroptosis Cancer
    Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib ditosylate monohydrate
  • HY-50898C

    GW572016 tosylate; GW2016 tosylate

    EGFR Ferroptosis Autophagy Cancer
    Lapatinib (GW572016) tosylate is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib tosylate
  • HY-50898A
    Lapatinib ditosylate
    Maximum Cited Publications
    81 Publications Verification

    GW572016 ditosylate; GW2016 ditosylate

    EGFR Autophagy Ferroptosis Cancer
    Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib ditosylate
  • HY-P991243

    EGFR PI3K Akt Cancer
    MP-RM-1 is a selective murine monoclonal antibody inhibitor targeting human epidermal growth factor receptor 3 (ErbB-3). MP-RM-1 blocks the activation of ErbB-3 induced by neuregulin 1 (NRG-1β) and promotes the internalization and degradation of ErbB-3, inhibiting downstream signaling pathways such as PI3K-Akt. MP-RM-1 is promising for research of ErbB-3 highly expressed solid tumors such as breast cancer, melanoma, and prostate cancer .
    MP-RM-1
  • HY-50898S2

    GW572016-d5; GW2016-d5

    Isotope-Labeled Compounds EGFR Autophagy Ferroptosis Cancer
    Lapatinib-d5 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib-d5
  • HY-50898S1

    GW572016-dd7 dihydrochloride; GW2016-dd7 dihydrochloride

    Isotope-Labeled Compounds EGFR Autophagy Ferroptosis Cancer
    Lapatinib-d7 dihydrochloride is the deuterium labeled Lapatinib dihydrochloride. Lapatinib (GW572016) dihydrochloride is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib-d7 dihydrochloride
  • HY-18609
    PD158780
    4 Publications Verification

    EGFR Cancer
    PD158780 is a potent EGFR family inhibitor with IC50s of 8 pM, 49, 52, 52 nM for EGFR, ErbB2, ErbB3, and ErbB4, respectively.
    PD158780
  • HY-50898S3

    GW572016-d4-1; GW2016-d4-1

    Isotope-Labeled Compounds EGFR Autophagy Ferroptosis Cancer
    Lapatinib-d4-1 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib-d4-1
  • HY-50898S

    GW572016-d4; GW2016-d4

    EGFR Autophagy Ferroptosis Cancer
    Lapatinib-d4 is the deuterium labeled Lapatinib (HY-50898). Lapatinib is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib-d4
  • HY-P991240

    EGFR Cancer
    CDX-3379 is a humanized monoclonal antibody inhibitor targeting ErbB3. CDX-3379 binds to ErbB3, blocking the dimerization of ErbB3 with other receptors, thereby inhibiting the phosphorylation of ErbB3. CDX-3379 can inhibit the growth and proliferation of tumor cells. CDX-3379 is promising for research of tumors expressing ErbB3 and NRG1, such as HNSCC .
    CDX-3379
  • HY-50898R

    GW572016 (Standard); GW2016 (Standard)

    Reference Standards EGFR Autophagy Ferroptosis Cancer
    Lapatinib (Standard) is the analytical standard of Lapatinib. This product is intended for research and analytical applications. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib (Standard)
  • HY-13272
    Dacomitinib
    20+ Cited Publications

    PF-00299804; PF-299804

    EGFR Apoptosis Cancer
    Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively .
    Dacomitinib
  • HY-50898S4

    GW572016-d7; GW2016-d7

    Isotope-Labeled Compounds Autophagy EGFR Ferroptosis Cancer
    Lapatinib-d7 (GW572016-d7) is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib-d7
  • HY-50898BR

    EGFR Autophagy Ferroptosis Cancer
    Lapatinib (ditosylate monohydrate) (Standard) is the analytical standard of Lapatinib (ditosylate monohydrate). This product is intended for research and analytical applications. Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib ditosylate monohydrate (Standard)
  • HY-50898AR

    EGFR Autophagy Ferroptosis Cancer
    Lapatinib (ditosylate) (Standard) is the analytical standard of Lapatinib (ditosylate). This product is intended for research and analytical applications. Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib ditosylate (Standard)
  • HY-W006886

    Amino Acid Derivatives Others
    Fmoc-(R)-2-(7-octenyl)Ala-OH is an amino acid derivative with an Fmoc protecting group that can be used to synthesize inhibitor peptides that combinatorially inactivate ErbB1, ErbB2, and ErbB3 .
    Fmoc-(R)-2-(7-octenyl)Ala-OH
  • HY-50898CS

    GW572016-d4 tosylate; GW2016-d4 tosylate

    Isotope-Labeled Compounds EGFR Autophagy Ferroptosis Cancer
    Lapatinib-d4 (GW572016-d4) tosylate is deuterium labeled Lapatinib (tosylate). Lapatinib (GW572016) tosylate is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib-d4 tosylate
  • HY-W777297

    Isotope-Labeled Compounds EGFR Autophagy Ferroptosis Cancer
    Lapatinib- 13C2, 15N Ditosylate is the 13C- and 15N-labeled Lapatinib ditosylate (HY-50898A). Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib-13C2,15N Ditosylate
  • HY-13272S3

    PF-00299804-d10; PF-299804-d10

    Isotope-Labeled Compounds EGFR Apoptosis Cancer
    Dacomitinib-d10 is deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively .
    Dacomitinib-d10
  • HY-13272S2

    PF-00299804-d10 dihydrochloride; PF-299804-d10 dihydrochloride

    Isotope-Labeled Compounds EGFR Apoptosis Cancer
    Dacomitinib-d10 dihydrochloride is the deuterium labeled Dacomitinib dihydrochloride. Dacomitinib (PF-00299804) dihydrochloride is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively .
    Dacomitinib-d10 dihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: